Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q2 FY2021 Earnings Presentation
31 slides from Morepen Laboratories's earnings presentation, Nov 9, 2020
Slide 1: Cover letter to stock exchanges
Date: 09/11/2020 To, National Stock Exchange oflndia Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 _ Symbol: MO_REPENLAB ScriIL-Code: 50028~ Subject: Investors Presentation (Q2' FY21) November,
Slide 2: Morepen Laboratories Q2'FY21 Investor Presentation
MOREPEN LABORATORIES LIMTED Q2'FY21 (Investor Presentation November 2020)
Slide 3: Disclaimer/ Confidentiality
Disclaimer/ Confidentiality: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implie
Slide 4: Highlights for the Quarter
Rs. in crores HIGHLIGHTS FOR THE QUARTER (Consolidated) Q2'FY21 Exponential growth CO ^57% ^99% Net Revenue 216.24 340.13 EBIDTA 17.87 35.49 35.49 ^566% Profit after Tax ^198% Profit before Tax ^566% EPS (Q2) 4.08 27.17 Q2'FY20 Q2'FY21 9.24 27.52 Rs. 0.09 Rs. 0.60 MOREPEN: Q2'FY21 Q2'FY20 Q2'FY21 Q2
Slide 5: Three Verticals
THREE VERTICALS BULK DRUGS (API) Strong portfolio of lifestyle drugs including anti- diabetics, antihypertensives, neuropsychiatric, anti- cancers and anti-virals DIAGNOSTIC DEVICES Home diagnostics including glucose meters, BP monitors, nebulisers, weighing scales, digital and IR thermometers, Oxim
Slide 6: The Journey of Growing Together
The Journey of Growing Together 200) “&Dr"Morepen' + Lounched Health Brond Dt Morepen. 1999 + Plant for finished dosage ot Sod + Launched OTC Generic Division + Launched Diagnostic Division- ‘Medipath * Morepen recaives USFDA approval forts Mosullhana Plant for menufectuing Loratadine srCr partied)
Slide 7: Manufacturing Facilities
APIs, R&D MANUFACTURING FACILITES Global Approvals/ International Standards APIs, R&D, Diagnostic Devices, Formulation, OTC Masulkhana (HP) Formulation Parwanoo (HP) Baddi (HP) MOREPEN: Q2'FY21
Slide 8: Baddi Facility (60 Acres)
BADDI FACILITY (60 ACRES) MOREPEN: Q2'FY21
Slide 9: Revenue Growth
Rs. in crores REVENUE GROWTH (Consolidated) Q2'FY21 1,000 Achieving New Milestones ^57% 862.55 CO 750 772.21 400 610.23 599.10 H1 500 300 340.13 ^72% ^38% Export 200 216.24 250 37.7% 100 Export 38% 0 Domestic 62% Q2'FY20 Q2"FY21 0 Domestic 62.3% FY'18 FY'19 FY'20 FY'21(H1) MOREPEN: Q2'FY21 Q2'FY21
Slide 10: Segment Wise Revenue
SEGMENT WISE REVENUE (Standalone) API Leads the Show Formulations 12% CO Formulations 17% Diagnostic Devices Export Export 41.4% 41% 25% Domestic Domestic 59%58.6% API Export 63% 39.4% Domestic Export 61% 39% Diagnostic Devices Domestic 60.6% 21% API H1'FY 20-21 62% API Share 62% -63% Export Share 3
Slide 11: Segment Wise Growth
Rs. in crores SEGMENT WISE GROWTH Q2'FY21 API and Devices grow exponentially 100 ^98% CO 90.35 75 ^60% 50 45.52 Diagnostic 25 Devices 200 0 Q2'FY20 Q2'FY21 185.69 150 100 116.37 API Business 50 Formulations Dr. Morepen OTC 40 -4% 25 ^53% 0 30 34.71 33.43 20 23.07 Q2'FY20 Q2'FY21 20 15 10 15.05 10 5
Slide 12: API Division
‘eo 2 ee 2 ~ API DIVISION i Seer? il ~~. Be.
Slide 13: API Portfolio
API PORTFOLIO Regulated Markets API High Value Drugs Complex Chemistry anti-allergy Multistage Synthesis anti-diabetic cholesterol-reducers Lifestyle Chronicle Diseases anti-hypertensive Consistent Demand High Growth Categories neuro-psychatric
Slide 14: API Growth
Rs. in crores API GROWTH 500 Trendsetting performance ^60% 473.95 API 400 413.05 200 339.08 347.75 H1 300 185.69 150 200 116.37 ^143% ^38% 100 Domestic 31.3% 50 100 Domestic 31% 0 Q2'FY20 Q2"FY21 0 Export FY'18 FY'19 FY'20 FY'21(H1) Export 69% 68.7% MOREPEN: Q2'FY21 Q2'FY21
Slide 15: API Exports to Regulated Markets
Rs. in crores 400 341.09 API 300 309.38 72% 200 234.68 244.71 H1 EXPORT Exporting to Regulated Markets 100 FY 19-20 0 FY'18 FY'19 FY'20 FY'21(H1) MOREPEN: Q2'FY21
Slide 16: Growing Exports
^10% Rs. in crores GROWING EXPORTS 30 27.23 24.64 Q2'FY21 ^16% 20 ^45% 20 10 15 16.18 0 75 13.95 Q2'FY20 Q2'FY21 66.81 API 10 EUROPE 50 ^220% 45.83 5 25 0 20 Q2'FY20 Q2'FY21 USA 15 17.74 0 Q2'FY20 Q2'FY21 10 APAC 8.06 5 0 Q2'FY20 Q2'FY21 OTHER 150 ^37% 127.56 100 92.48 50 0 Q2'FY20 Q2'FY21 TOTAL MOR
Slide 17: Intellectual Property
INTELLECTUAL PROPERTY The Growth Engine API 125 111 Patents* DMFs 9 25 USA . Europe . Japan China- IDLs New Products China . Taiwan . Australia *Active 55 MOREPEN: Q2'FY21
Slide 18: API Expansion Project
New API EXPANSION PROJECT Project Site Major Expansion after 22 years Govt. fo India supporting API expansions plans and rs. 178 Project Cost crores 3 years Completion time 700 New Hiring people has also launched performance linked incentive scheme Make in 2000 Capacity MT 40 New Products rs. 4217 P
Slide 19: Expanding API Market 15X
EXPANDING API MARKET New Molecules add 15X market size 50 Market Size of the Product Basket Total global market size of the all the products USD Billion API which the Company is presently selling is only $4.004 Billion and in coming five years is going to 40 42.199 go down to $2.825 Billion since th
Slide 20: Diagnostics Devices
DIAGNOSTICS DEVICES
Slide 21: Diagnostic Devices
Rs. in crores DIAGNOSTIC DEVICES 200 Manufactured in India ^98% MEDICAL DEVICES 168.35 150 139.75 H1 136.91 100 90.35 100 103.35 75 50 45.52 50 25 0 Q2'FY20 Q2"FY21 0 FY'18 FY'19 FY'20 FY'21(H1) MOREPEN: Q2'FY21
Slide 22: Key Products
KEY PRODUCTS Q2'FY21 A significant increase API ^74% ^185% Gluco Meters BP Meters ^311% ^43% Thermometers Nebulisers MOREPEN: Q2'FY21
Slide 23: Glucometer Share of Gross Revenue
MEDICAL DEVICES 7 1% G L U C O M E T E R SHARE OF GROSS REVENUE FY 19-20
Slide 24: Gluco Monitors Market Leadership
GLUCO MONITORS Market Leadership YTD SEP'20 DATA MEDICAL DEVICES 500 4 MILLION INSTALLATIONS MILLION STRIPS SOLD Q2'FY21: Q2'FY21: 0.408 million 60 million test New Meters strips sold Installed MOREPEN: Q2'FY21
Slide 25: Finished Dosages
x FINISHED DOSAGES - i A™
Slide 26: Formulation
Rs. in crores FORMULATION Q2'FY21 200 Branded & Generics FINISHED DOSAGES 150 153.17 40 -4% 137.57 100 110.51 30 34.71 33.43 20 H1 50 56.47 10 0 Q2'FY20 Q2"FY21 0 FY'18 FY'19 FY'20 FY'21 (H1) Affected by Covid-19 Q-o-Q recovery coming MOREPEN: Q2'FY21
Slide 27: Dr. Morepen
Morepen” ail fae
Slide 28: Dr. Morepen
Rs. in crores DR. MOREPEN Q2'FY21 75 Health in your hands 64.63 OTC 50 54.38 ^53% 25 48.89 44.76 H1 23.07 20 25 15 15.04 10 5 0 0 FY'18 FY'19 FY'20 FY'21(H1) Q2'FY20 Q2"FY21 MOREPEN: Q2'FY21
Slide 29: Financial Highlights
Rs. in crores FINANCIAL HIGHLIGHTS (Consolidated) Q2'FY21 Exponential Growth ^57% 30 ^198% 400 27.52 300 340.13 20 200 216.24 10 100 9.24 0 0 Q2'FY20 Q2'FY21 Q2'FY20 Q2'FY21 Net Revenue Profit before tax ^50% ^99% ^566% 0.75 ^566% 400 30 40 27.17 300 30 35.49 0.60 304.64 20 0.5 200 20 198.37 10 0.25
Slide 30: Balance Sheet / Ratios (H1'FY21)
Rs. in crores BALANCE SHEET/ RATIOS (H1'FY21) H1'FY'21 Exponential Growth 125 500 100 250 119.65 119.65 241.05 100 400 450.66 75 89.96 89.96 200 403.71 194.10 75 300 150 50 50 200 100 25 25 100 50 0 0 0 0 MAR'20 SEP'20 MAR'20 SEP'20 MAR'20 SEP'20 MAR'20 SEP'20 Preference Capital Total Capital Employ
Slide 31: Thank you
Thank you
Morepen Laboratories — Q2 FY2021 Earnings Presentation on 6ix